VACCINES. Red Biotechnology
|
|
- Denis Horton
- 5 years ago
- Views:
Transcription
1 VACCINES Red Biotechnology
2 1. To recount the history of vaccines 2. To explain what vaccines are made of and how they work 3. To discuss the impact of vaccines and issues related to their use Learning Outcomes
3 1. To recount the history of vaccines Learning Outcome #1
4 The First Vaccine
5 Term was derived from Virolae vaccinae by Edward Jenner Vaccination
6 2. To explain what vaccines are made of and how they work Learning Outcome #2
7 A biological material that STIMULATES the immune system to RECOGNIZE and DEFEND the body against a SPECIFIC agent of disease What Is A Vaccine
8 Carbohydrate antigen Dead or attenuated pathogen Antibody Protein antigen Active Component of Vaccine
9 Taking the vaccine. Antibodies destroy pathogen. Antibody creation. If pathogen is met. Memory cells are formed.
10 Prophylactic Prevents the development of a disease Therapeutic Treats an ongoing disease Vaccines Can Be
11 TABLE 1 Dyer et al Drug Discovery Today. 11: 21/22 Ongoing clinical trials for vaccines in addictions and chronic diseases (limited to company-sponsored trials in non-cancer, non-allergy and non-infection indications) Indication Conjugated target Carrier protein Company Clinical status Addiction Nicotine Virus-like particles Cytos Phase II Addiction Nicotine Pseudomonas aeruginosa exoprotein A Nabi Phase II Addiction Nicotine Recombinant cholera toxin B Xenova Phase I Addiction Cocaine Recombinant cholera toxin B Xenova Phase II Hypertension Angiotensin II Virus-like particles Cytos Phase I/II Cholesterol management Cholesterol ester transferase Tetanus toxoid Avant Phase II Gastro-esophageal reflux disease Gastrin 17 Diptheria toxoid Aphton Phase II Obesity Ghrelin Virus-like particles Cytos Phase I/II Psoriasis Tissue necrosis factor Virus-like particles Cytos Phase I/II Hypertension Angiotensin I Keyhole limpet hemocyanin Protherics Under reformulation Alzheimer s Ab-fragment Virus-like particles Novartis/Cytos Phase I Alzheimer s Ab-fragment Not disclosed Wyeth/Elan Phase I Second Vaccine Revolution
12 Third Vaccine Revolution
13 3. To discuss the impact of vaccines and issues related to their use Learning Outcome #3
14
15 Expanded Program on Immunization EPI began in the Philippines in July 1979: sustaining high routine Full Immunized Child (FIC) coverage of at least 90% in all provinces and cities; sustaining the polio-free country for global certification; eliminating measles by 2008; and eliminating neonatal tetanus by 2008 Vaccines In Action
16
17
18 A. Research on the role and actions of the following in relation to the dengvaxia mass vaccination in the Philippines. List all the events and related data (e.g. statistics) obtained from your research. Be prepared to share facts and opinion in response to interview questions in B. Sanofi DOH Formulary Executive Council WHO B. Read the CNN timeline on the dengvaxia vaccination in the Philippines (see Learning Tools). Prepare interview questions addressed to each group mentioned in A which will lead to a) an understanding on how the dengvaxia issue arose, b) the implications, and c) what could have been/can be done to address this national problem. Group Homework
19 HOST Questions Questions were logical, comprehensive and thought provoking Questions were logical and comprehensive Questions were logical but could have added more to cover all aspects of the issue Questions did not address the issues Comprehension The hosts clearly understood the discussion in-depth and provided appropriate additional insights with confidence. The hosts clearly understood the discussion in-depth and provided appropriate additional insights with ease. The hosts seemed to understand the main points of the discussion and presented those with ease. The hosts did not show an adequate understanding of the discussion. Information processing The hosts clearly identified and summarized all the main issues, their implications, and solutions to address them. The hosts identified and summarized most of the main issues, their implications, and solutions to address them. The hosts identified and summarized some of the main issues, their implications, and solutions to address them. The hosts failed to identify and summarize the main issues, their implications, or solutions to address them. Organization The hosts were able to exhaustively thresh out the major information and issues related to the topic in a manner that helps the audience to follow the discussion. The hosts were able to thresh out the major information and issues related to the topic in a manner that helps the audience to follow the discussion. The hosts were able to thresh out the major information and issues related to the topic, but was organized in a slightly confusing manner. The hosts were not able to thresh out the major information and issues related to the topic, or the discussion was difficult to follow. Rubrics for Talk Show
20 PANEL Comprehension The team clearly understood the discussion in-depth and presented their information forcefully and convincingly. The team clearly understood the discussion in-depth and presented their information with ease. The team seemed to understand the main points of the discussion and presented those with ease. The team did not show an adequate understanding of the discussion. Facts/Statistics Every major point was well supported with several relevant facts, statistics and/or examples. Every major point was adequately supported with relevant facts, statistics and/or examples. Every major point was supported with facts, statistics and/or examples, but the relevance of some was questionable. Every point was not supported. Organization All discussions were clearly tied to an idea (premise) and organized in a tight, logical fashion. Most discussions were clearly tied to an idea (premise) and organized in a tight, logical fashion. All discussions were clearly tied to an idea (premise) but the organization was sometimes not clear or logical. Discussions were not clearly tied to an idea (premise). Critical Thinking Formulated a clear and precise personal point of view, and thoroughly discussed implications, conclusions, and consequences considering all relevant assumptions, contexts, data, and evidence. Formulated a clear and precise personal point of view, and discussed implications, conclusions, and consequences, considering all relevant assumptions, contexts, data, and evidence. Formulated a clear and precise personal point of view, but discussion implications, conclusions, and consequences needs improvement. Point of view not clearly formulated, or assumptions, contexts, data, and evidence were not considered in the discussions. Rubrics for Talk Show
Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More information1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More informationProposed Mechanisms for Aggregate Induced Immunogenicity
Proposed Mechanisms for Aggregate Induced Immunogenicity Science 262, 1448-1451 1 rganization: high low absent Antibody response +++ + - Induction of auto-antibodies +++ - - Recombinant Protein Therapy
More informationTherapeutic Proteins BIT 230
Therapeutic Proteins BIT 230 CLOTTING Haemophilia Benefix Blood Products ANTICOAGULANT THROMBOLYTIC AGENTS tissue plasminogen activator streptokinase Coagulation pathway Factor VIII (Haemophilia A) Factor
More informationThe genetic material is arranged differently in the cells of bacteria compared with animal and plant cells.
Some infections are caused by bacteria. The genetic material is arranged differently in the cells of bacteria compared with animal and plant cells. Describe two differences. Tuberculosis (TB) is an infection
More informationMicrobial Biotechnology agustin krisna wardani
Microbial Biotechnology agustin krisna wardani 1. The Structure of Microbes Microbes (microorganisms) are tiny organisms that are too small to be seen individually by the naked eye and must be viewed with
More informationAdaptive Immunity: Specific Defenses of the Host
PowerPoint Lecture Presentations prepared by Bradley W. Christian, McLennan Community College C H A P T E R 17 Adaptive Immunity: Specific Defenses of the Host The Adaptive Immune System Adaptive immunity:
More informationQuality Control in Biotechnology. Andrew Lees, Ph.D. Scientific Director Fina BioSolutions LLC.
Quality Control in Biotechnology Andrew Lees, Ph.D. Scientific Director Fina BioSolutions LLC www.finabio.com Fina Chemical drugs vs Biologicals Chemical drugs can be precisely defined Physical chemical
More informationM1. (a) stomach and pancreas correctly labelled 1. bacteria not killed (by stomach acid / HCl) and so they damage mucus lining 1
M. (a) stomach and pancreas correctly labelled (b) bacteria not killed (by stomach acid / HCl) and so they damage mucus lining so acid / HCl damages stomach tissue / causes an ulcer allow bacteria infect
More informationImmune System. Viruses vs. Bacteria
Immune System Viruses vs. Bacteria Concept Map Section 19-1 Bacteria are classified into the kingdoms of Eubacteria Archaebacteria include a variety of lifestyles such as live in harsh environments such
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationVaccine Cuisine EDIBLE VACCINES. Nina Gloriani Barzaga, M.D.,Ph.D. University of the Philippines Manila
Slide 1 Plant Made Pharmaceuticals EDIBLE VACCINES Vaccine Cuisine Nina Gloriani Barzaga, M.D.,Ph.D. University of the Philippines Manila 3 rd Asian Biotechnology Conference, Manila Nov 9-10, 2006 Slide
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationGenetic tests are available for hundreds of disorders. DNA testing can pinpoint the exact genetic basis of a disorder.
Human DNA Analysis Human DNA Analysis There are roughly 6 billion base pairs in your DNA. Biologists search the human genome using sequences of DNA bases. Genetic tests are available for hundreds of disorders.
More informationName: Score: / Quiz 7 on Pharmaceutical Biotechnology. Part 1. A. organ transplantation. B. xenotransplatation. C. animal cloning. D.
Name: Score: / Quiz 7 on Pharmaceutical Biotechnology Part 1 Immune cells have been genetically modified to treat cancer. Stem cells, as well as other cells in tissues and organs in the human body, have
More informationIVI and Technology Transfer. 14 th DCVMN Meeting Hanoi, October 7-9, 2013
IVI and Technology Transfer 14 th DCVMN Meeting Hanoi, October 7-9, 2013 5 17 months: 46% - 27% - 18 months 6-12 weeks: 27% - 15 % 86 / 78% IVI Vision & Mission VISION Developing countries free of suffering
More informationChapter 5. Microbial Biotechnology. PowerPoint Lectures for Introduction to Biotechnology, Second Edition William J.Thieman and Michael A.
PowerPoint Lectures for Introduction to Biotechnology, Second Edition William J.Thieman and Michael A.Palladino Chapter 5 Microbial Biotechnology Lectures by Lara Dowland Chapter Contents 5.1 The Structure
More informationCourse Descriptions. BIOL: Biology. MICB: Microbiology. [1]
Course Descriptions BIOL: Biology http://www.calendar.ubc.ca/vancouver/courses.cfm?code=biol [1] BIOL 112 (3) Biology of the Cell The principles of cellular and molecular biology using bacterial and eukaryotic
More informationThere was a reduction in number of new individuals being vaccinated / vaccine uptake was lower / higher number of babies; 1 [7]
1. (a) Antibody binds/eq/recognises only to cancer cells; because of antibody-antigen binding/eg; enzyme activates the drug; at cancer cells only; max 3 B lymphocytes produce antibodies/involved in humoral
More informationRegulatory Experience for a Gene Therapy Product in a Large Phase II European Study. Disclaimer
Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study Catherine Mathis Director of Regulatory Affairs transgene 1 Disclaimer The views and opinions expressed in the following
More information21 st Century Herpes Solutions. William Halford, PhD RVx, Chief Science Officer
21 st Century Herpes Solutions William Halford, PhD RVx, Chief Science Officer Scope of Herpes Problem: by the numbers A major public health concern HSV-1 and/or HSV-2 HSV-2 infections ~100 million recurrent
More informationPharmabiotics: a Regulatory Hurdle in Europe
Pharmabiotics: a Regulatory Hurdle in Europe Dr. Magali Cordaillat-Simmons PRI Executive Scientist Raleigh, NC, USA September 8th, 2014 PHARMABIOTICS: A REGULATORY HURDLE IN EUROPE I. Introduction to Pharmabiotics
More informationStudents should be able to explain how the spread of diseases can be reduced or prevented.
4.3 Infection and response Pathogens are microorganisms such as viruses and bacteria that cause infectious diseases in animals and plants. They depend on their host to provide the conditions and nutrients
More informationList of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.
Faculty 1 Adolescent Psychiatry Psychiatry 2 Anti Cancer Agents in Medicinal / Pharma & Quality 3 Anti-Infective Agents Pharmaceutical Microbiology 4 Anti-Inflammatory & Anti- Allergy Agents in Medicinal
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationMonoclonal Antibodies for Treatment and Prevention of HIV-1 CROI Charles Boucher Erasmus MC
Monoclonal Antibodies for Treatment and Prevention of HIV-1 CROI 2018 Charles Boucher Erasmus MC Introduction: Human monoclonal antibodies Monoclonal Antibodies: Are identical immunoglobulins made by clone
More informationSustaining long-term growth by focusing on our customers
Strategy in action Sustaining long-term growth by focusing on our customers Our capabilities and customer focused strategy are opening growth opportunities in addressable markets of approximately $8 billion.
More informationRSV Vaccine Development Status Update
Photo: PATH/Doune Porter RSV Vaccine Development Status Update WHO RSV Surveillance Pilot 18-20 Dec 2017 Washington DC Deborah Higgins PATH Photo credit CENTER FOR VACCINE INNOVATION AND ACCESS PATH RSV
More informationDR NEIL FISHER. Helicon Medical Writing Ltd, Director
PROFILE I am an experienced writer, skilled in writing and editing a wide range of medical communications and healthcare education documents for a variety of audiences. Integral to this is my command of
More informationANTIBODIES. Agents of Immunity
ANTIBODIES Agents of Immunity - Antibodies are: The Organization What are they? Protective agents of the immune system Neutralize foreign agents called antigens Essential part of the Adaptive Immune System
More informationDr: RAWIA BADR Associate Professor of Microbiology&Immunology
Dr: RAWIA BADR Associate Professor of Microbiology&Immunology Cell culture Commonly refers to the culture of animal cells and tissues, while the more specific term plant tissue.culture is used only for
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationPresidential Commission for the Study of Bioethical Issues 2 nd meeting September
Presidential Commission for the Study of Bioethical Issues 2 nd meeting September 13 14 2010 David B. Weiner, Ph.D. Professor Department of Pathology and Laboratory Medicine University of Pennsylvania
More informationLondon, 11 October 2006 Doc. Ref. EMEA/CHMP/BWP/271475/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency 1 2 London, 11 October 2006 Doc. Ref. 3 4 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) 5 DRAFT 6 7 GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY MEDICINAL
More informationIMMUNOBIOLOGY : AN INTRODUCTION
31 IMMUNO : AN INTRODUCTION We all get infections, but some of us fall sick more frequently than others. This is related to the immune system. Proper functioning of immune system protects us from the infections.
More informationTHE FIRST OBSERVATIONS
THE FIRST OBSERVATIONS ROBERT HOOK FIRST TO SEE CELLS WHILE OBSERVING A THIN SLICE OF CORK MARKED THE BEGINNING OF THE CELL THEORY: THEORY THAT ALL LIVING THINGS ARE COMPOSED OF CELLS ANTON VAN LEEUWENHOEK
More informationMastering Immunity. ProPresent. Antigen Presentation Assay. Copyright ProImmune Limited All Rights Reserved
Mastering Immunity ProPresent Antigen Presentation Assay Background Options to explore T cell epitopes Prediction (fast, inexpensive, accuracy?, does not confirm epitope) Proliferation assays (well suited
More informationIMMUNOBIOLOGY : AN INTRODUCTION
Immunobiology : An Introduction MODULE - 5 30 IMMUNO : AN INTRODUCTION We all get infections, but some of us fall sick more frequently than others. This is related to the immune system. Proper functioning
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationChapter 3 The Immune System
Chapter 3 The Immune System Why is the Immune System Important? Why is the Immune System Relevant to HIV? T Lymphocyte Infected by HIV Brief History of Immunology Immunity- Observation reported in 430
More informationAnja Holm Danish Medicines Agency. Genetic vaccines Oslo, 2008
Anja Holm Danish Medicines Agency Genetic vaccines Oslo, 2008 Ministry of Food, Agriculture and Fisheries Danish Veterinary Institute Technical review & discussion of safety issues Author: Anja Holm. Anja
More information21 st Century Herpes Solutions. William Halford, PhD RVx, Chief Science Officer
21 st Century Herpes Solutions William Halford, PhD RVx, Chief Science Officer Scope of Herpes Problem A major public health concern HSV-1 and/or HSV-2 HSV-2 infections ~100 million recurrent herpes severe
More informationTarget-mediated Clearance and Immunogenicity two sides, one coin. Daren Austin, PhD Senior Director and Head Biopharm Clinical Pharmacology
Target-mediated Clearance and Immunogenicity two sides, one coin Daren Austin, PhD Senior Director and Head Biopharm Clinical Pharmacology Pharmacokinetic determinants of therapeutic proteins Pharmacokinetic
More informationBEH.462/3.962J Molecular Principles of Biomaterials Spring 2003
Lecture 17: Drug targeting Last time: Today: Intracellular drug delivery Drug targeting Reading: T.J. Wickham, Ligand-directed targeting of genes to the site of disease, Nat. Med. 9(1) 135-139 (2003) Drug
More information1 R01 AI VMD HALFORD, W
1 R01 AI104935-01 2 VMD 1R01AI104935-01 ILLIAM CRITIQUE 1: Significance: 5 Investigator(s): 2 Innovation: 5 Approach: 8 Environment: 2 Overall Impact: This application proposes to develop a recombinant
More informationCalendar. The Clear Solution to Reach the Global Biopharma Audience. INTERNATIONAL
The Clear Solution to Reach the Global Biopharma Audience yvdavyd/getty Images & blackred/e+/getty Images 2017 EDITOrial Calendar Editorial Coverage Special Themed Issues January Biopharma Outlook for
More informationibio, Inc. Holds Annual Meeting in College Station, Texas
April 7, 2016 ibio, Inc. Holds Annual Meeting in College Station, Texas NEW YORK, NY -- (Marketwired) -- 04/07/16 -- ibio, Inc. (NYSE MKT: IBIO) - Speaking to shareholders at the ibio, Inc. (NYSE MKT:
More information1 R21 AI A1 2 VMD HALFORD, W
1 R21 AI081072-01A1 2 VMD 1R21AI081072-01A1 ILLIAM RESUME AND SUMMARY OF DISCUSSION: The proposed study is to develop safe and effective live attenuated vaccines against herpes simplex virus 2 by using
More informationIntroduction to process development for vaccine production. DCVMN 10 March 2017
Introduction to process development for vaccine production DCVMN 10 March 2017 Need for updated vaccine processing and process optimization for global access Process development and optimization training
More informationStability of sub-unit vaccines measured with the UNit label-free stability platform
Application Note Stability of sub-unit vaccines measured with the UNit label-free stability platform Introduction Sub-unit vaccines and the need for adjuvants Of the many classes of vaccines that have
More informationGuideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics
Provisional Translation (as of April 19, 2013) PFSB/ELD Notification No. 0304007 March 4, 2009 To: Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food
More informationFACTSHEET. Introduction. Antibodies ALTERNATIVES TO ANTIBIOTICS
FACTSHEET ALTERNATIVES TO ANTIBIOTICS Introduction Due to antibiotic resistance and the long-term lack of antibiotic discovery, alternative treatments and effective prevention strategies for bacterial
More informationHomework focus: SB5a Health and Disease
SB5a Health and Disease Describe what is meant by the terms health and disease. Describe how communicable and non-communicable diseases differ. Outline the role of the immune system in protecting against
More informationDevelopment and challenges to monoclonal antibodies for passive immunization
Development and challenges to monoclonal antibodies for passive immunization Erin Sparrow 21 June 2017 1 A brief history of serum derived passive immunization Concept developed by von Behring & Kitasato
More informationBiotechnology Overview
Biotechnology Overview What is Biotechnology? The use of living organisms to solve problems or make useful products Early Biotechnology Microbes such as yeast and bacteria to make useful food products
More informationAdvances in Vaccine and Immunization Technologies
Advances in Vaccine and Immunization Technologies Cristina Cassetti, Ph.D. Translational Science Program Director Virology Branch Division of Microbiology and Infectious Diseases National Institute of
More informationComments to the Draft Model Guidelines by the Biotechnology Industry Organization
BY HAND DELIVERY Lynn Lang United States Pharmacopeia 12601 Twinbrook Parkway Rockville, MD 20852-1790 Re: Comments to the Draft Model Guidelines by the Biotechnology Industry Organization Dear Ms. Lang:
More informationYoung Innovators 2011
Young Innovators 2011 Formulation of Novel Particulate Breast Cancer Vaccines using Spray Drying and In Vivo Evaluation of Vaccine Efficacy 2011 AAPS Graduate Student Symposium Awards in Biotechnology
More informationResearch Progress of Genetic Immunization and Confronting Problems
2018 International Conference on Computer Science and Biomedical Engineering (CSBIOE 2018) Research Progress of Genetic Immunization and Confronting Problems Zhang Dandan 1, Gao Chengguang 2, * 1 College
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON PHARMACEUTICAL AND BIOLOGICAL ASPECTS OF COMBINED VACCINES
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON PHARMACEUTICAL
More informationBiology 1a Summary B1.1 KEEPING HEALTHY B1.1.1 Diet and exercise
Biology 1a Summary B1.1 KEEPING HEALTHY B1.1.1 Diet and exercise a) A diet is what you eat! A healthy diet contains the right balance of the different foods you need and the right amount of energy. Carbohydrates,
More informationHuman Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders
Human Genome Editing: Science, Ethics, and Governance Highlights for Industry Stakeholders Background Advances in genome editing, especially the CRISPR/Cas9 genome editing system, have generated tremendous
More informationGrowing Together: How Viruses Have Shaped Human Evolution. Shirlee Wohl Katherine Wu
Growing Together: How Viruses Have Shaped Human Evolution Shirlee Wohl Katherine Wu What comes to your mind when you hear the word virus? flu public health cold vaccine infection disease cough biology
More informationToday is Tuesday, February 26 th, 2019
Today is Tuesday, February 26 th, 2019 Pre-Class: Today we are reviewing. Have your questions ready! Today s Agenda Review Review Getting shot in the eyeball? Review Review Game Rules I will ask a question
More informationPreclinical study. Assist.Prof. Witthawat Wiriyarat Faculty of Veterinary Science, Mahidol University
Preclinical study Assist.Prof. Witthawat Wiriyarat Faculty of Veterinary Science, Mahidol University Overviews Principle of animal use Biological activity/pharmacodynamics Animal species and model selection
More informationBiotechnology: Unlocking Nature s Secrets
Course Syllabus Biotechnology: Unlocking Nature s Secrets Course Description Can we bring back extinct species? Will the cures for cancer, malaria, and other diseases come from the combination of natural
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationThe definitions given below have been selected and restricted to those that are likely to be useful to users of this OIE Terrestrial Manual.
The definitions given below have been selected and restricted to those that are likely to be useful to users of this OIE Terrestrial Manual. Absorbance, also termed optical density (OD), describes the
More informationSynagis (Pediatric RSV)
Synagis (Pediatric RSV) Forecast and Market Analysis to 2022 GDHC1135DFR / Published April 2013 Executive Summary Table below provides a summary of the key metrics in the pediatric RSV prophylactics market
More informationDRUG REGISTRATION REGULATION
DRUG REGISTRATION REGULATION Registration Categories and Application Information Items Requirements of Biological Products Part I I Therapeutic Biological Products Registration Categories 1) Biological
More informationPre-clinical Case Studies of Biologic Therapeutics
Pre-clinical Case Studies of Biologic Therapeutics A Multi-Faceted Strategy of Testing Immunotoxic Potential and Pharmacodynamic Properties of Immunomodulatory Monoclonal Antibodies Jennifer Wheeler Bristol-Myers
More informationPHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14
PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14 Submitted resources from physician organization representatives were mapped
More informationNanoAssemblr Benchtop. Develop Future Nanomedicines
NanoAssemblr Benchtop Develop Future Nanomedicines Develop the Future of Medicine Overcome key challenges in advancing nanomedicines: Challenges with conventional production methods Solutions with the
More informationBioWorld s. PARTNER in FOCUS: Immunomic Therapeutics Inc. AN ADVERTISING SERVICE FROM BIOWORLD
BioWorld s PARTNER in FOCUS: Immunomic Therapeutics Inc. AN ADVERTISING SERVICE FROM BIOWORLD THE REMARKABLE SCIENCE BEHIND LAMP TECHNOLOGY AND ITS POTENTIAL TO TREAT HUMAN DISEASE The body s own immune
More informationWorkshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing
Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing Session 7: National regulatory authority s role in product commercialization, licensing and innovation of influenza vaccines
More informationGene Therapy: The Basics. Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University
Gene Therapy: The Basics Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University Definition of gene therapy Gene therapy is the introduction of nucleic acids (e.g. DNA/genes) into somatic
More informationCharacterization of Glycoconjugate Vaccines from a Regulatory Perspective
Characterization of Glycoconjugate Vaccines from a Regulatory Perspective Willie F. Vann, Chief Laboratory of Bacterial Polysaccharides CBER/FDA Bethesda, Maryland USA Many Pathogenic Bacteria are Encapsulated
More informationPartnering for Impact Human Health Therapeutics
Partnering for Impact Human Health Therapeutics Bernard Massie General Manager Human Health Therapeutics Partnering for Impact in Biologics and Vaccines NRC s Human Health Therapeutics (HHT) portfolio
More informationBiotechnology: Unlocking Nature s Secrets
Course Syllabus Biotechnology: Unlocking Nature s Secrets Course Code: EDL052 Course Description How is technology changing the way we live? Is it possible nature can provide all the answers to some of
More informationAn analysis of the Swedish Biotech Pipeline April, The Swedish Biotechnology Industry Organization
An analysis of the Swedish Biotech Pipeline April, 2007 The Swedish Biotechnology Industry Organization 0 A Survey of the Swedish Biotech pipeline In February-March 2007 a survey of the Swedish biotech
More informationGENERAL BACTERIOLOGY
GENERAL BACTERIOLOGY Dr. Waleed Eldars Lecturer of Medical Microbiology and Immunology Faculty of Medicine Mansoura University Growth requirements of Bacteria A) Nutrition Basic elements: Carbon and Nitrogen
More informationHow New Media Changes Pharmaceutical DTC Advertising
How New Media Changes Pharmaceutical DTC Advertising Thursday, April 16, 2009 Meredith Abreu Ressi Vice President of Research, Manhattan Research mressi@manhattanresearch.com Jeff Hitchcock President and
More informationRisk-based testing for anti-drug neutralizing antibodies during development of biological therapeutics
Risk-based testing for anti-drug neutralizing antibodies during development of biological therapeutics April 18 th, 2016 AAPS National Biotechnology Conference, Boston, MA Shalini Gupta, PhD Amgen Inc.
More informationBlood. Intermediate 2 Biology Unit 3 : Animal Physiology
Blood Intermediate 2 Biology Unit 3 : Animal Physiology Composition of Blood Blood contains Red blood cells White blood cells platelets plasma Plasma Watery, yellowish fluid Suspended in plasma Proteins
More informationRSV F Nanoparticle Vaccine: Update Gregory M. Glenn M.D., SVP R&D
RSV F Nanoparticle Vaccine: Update Gregory M. Glenn M.D., SVP R&D Summary of Findings in Recent Clinical Trials International Society of Vaccines October 26, 2014 1 www.novavax.com 2 The Problem with RSV
More informationZIKAVAX PARTNERSHIP. Dr Odile LEROY DCVMN Seoul 26 th September 2017
ZIKAVAX PARTNERSHIP Dr Odile LEROY DCVMN Seoul 26 th September 2017 1 Product Development Partnership THE EUROPEAN VACCINE INITIATIVE IS A PRODUC T DEVELOPMENT PARTNERSHIP WHICH AIMS TO ACCELERATE THE
More informationUpdate from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017
Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017 Outline Products regulated Significance of complex biologics Product and process Cutting
More informationWHO vaccine standardization: an update
PDVAC WHO vaccine standardization: an update Dr, WHO/HIS/EMP/TSN/NSB 10 th June 2016 Geneva Outline Standardization and regulatory evaluation of vaccines and biotherapeutic products Development of measurement
More informationA Guide for Developing Health Research Knowledge Translation (KT) Plans
A Guide for Developing Health Research Knowledge Translation (KT) Plans Adapted from: A Guide for Assessing Health Research Knowledge Translation Plans 2007 A Guide for Assessing Health Research Knowledge
More informationFirst Place Essay. Katie P.
First Place Essay Katie P. Eighth Grade West Reading, PA 19611 Bioscience research is seeking information by exploring life's processes and diseases. It has helped many scientists understand how the body
More information7TH E-NEWSLETTER. 7 th EBOVAC2. e-newsletter
7 th EBOVAC2 e-newsletter November 2018 1 Welcome to the EBOVAC2 e-newsletter! EBOVAC2: Getting up to date The EBOVAC2 project is one of 8 projects funded under the IMI Ebola+ program that was launched
More informationCOMPARABILITY OF NOVEL THERAPEUTICS: CASE STUDIES FOR A BISPECIFIC T-CELL ENGAGER AND ONCOLYTIC VIRUS. FRANK MAGGIO, Ph.D. PRODUCT QUALITY PRINCIPAL
COMPARABILITY OF NOVEL THERAPEUTICS: CASE STUDIES FOR A BISPECIFIC T-CELL ENGAGER AND ONCOLYTIC VIRUS FRANK MAGGIO, Ph.D. PRODUCT QUALITY PRINCIPAL BLINATUMOMAB MECHANISM OF ACTION Apoptotic Cell Death
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationIntroducing Immunomic Therapeutics Expanded Technology Platform: UNITETM
Introducing Immunomic Therapeutics Expanded Technology Platform: UNITETM Immunomic Therapeutics is a privately-held, clinical stage biotech company developing modern DNA and RNA vaccines for allergic diseases
More informationANTIGENS MODULE 56.1 INTRODUCTION OBJECTIVES. Notes
56 ANTIGENS 56.1 INTRODUCTION Common perception about an antigen is that it is a substance which produces antibodies and react with them. However, it is not entirely correct particularly in view of closely
More informationBWC/CONF.IV/4/Add.1 21 November Original: ENGLISH. Geneva, 25 November - 6 December 1996
FOURTH REVIEW CONFERENCE OF THE PARTIES TO THE CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION BWC/CONF.IV/4/Add.1
More informationLinker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p.
Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials Introduction p. 1 Roles of Regulatory Scientists p. 2 Product Development and Availability p. 2 Data Requirements
More informationGuidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines
Annex 2 Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines Introduction 61 Background 62 Scope 62 General considerations 63 Terminology 65 Part A. Manufacturing and quality
More informationELISA IMMUNOASSAY FOR HUMAN
Unit 6/ Module 1 /Version A pg. 1 California Lutheran University s Enriched Science (Clues) and California State University Program for Education and Research in Biotechnology (C-SUPERB) ELISA IMMUNOASSAY
More information